Athenex, Inc.
ATNXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ATNX. That does not mean none is planned.
Get an email about ATNX's next catalysts
Track Athenex (ATNX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Metastatic Breast Cancer
1 drug in this indication
Bone-Metastatic, Castration-Resistant Prostate Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Athenex, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Athenex, Inc.'s (ATNX) pipeline across Phase 3. Its lead program is KX2-391 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Athenex, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Athenex, Inc. (ATNX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATNX biotech catalysts?→
Add ATNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Athenex, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.